14 June 2022
Rapharma received registration certificate ËÏ-¹(000744)-(ÐÃ-RU) for its drug Oliramus drug (INN Everolimus) from the Ministry of Health of the Russian Federation. The drug will be available to patients in three dosages (2.5 mg, 5 mg, and 10 mg). This is reported on the company’s official website.
Oliramus antitumor therapy is a protein kinase inhibitor (mammalian target of rapamycin (mTOR) inhibitor) for oral administration. The drug is indicated for adult patients with the following conditions:
“Oliramus acts by suppressing protein kinase, thereby reducing blood supply to the tumor and slowing down the growth and spread of cancer cells. The efficacy, tolerability and safety of Everolimus has been confirmed in a large number of clinical trials,” the report says.
AO Rapharma, together with ZAO PharmFirma Sotex, forms the basis of the production segment of Protek group, the company stressed.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Russia has expanded the mandatory health insurance program for 2024-2026
29 March 2024
Russian scientists have developed new TB vaccines for both injection and nasal administration.
29 March 2024
The overall mortality rate of the population in Russia decreased by 7% in 2023
28 March 2024
Russia to collaborate with Hungary and Serbia in nuclear medicine
28 March 2024